Literature DB >> 33332756

Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period.

Samir El Sayed1, Doaa Shokry2, Sarah Mohamed Gomaa3.   

Abstract

BACKGROUND: Individuals infected by the novel coronavirus (SARS-CoV-2) have experienced different psychiatric manifestations during the period of infectivity and post-COVID-19 infection. Fatigue and anhedonia are among the frequently reported manifestations after recovery from this novel viral pandemic, leading to early evaluation of those patients and proper management of their complaints which have a drastic burden on different domains of life. Also, the period after recovery might have an effect on the severity of these two psychiatric presentations. AIM OF THE WORK: This cross-sectional observational study aimed to investigate the occurrence of post-COVID-19 fatigue and anhedonia and whether the duration after 2 consecutive PCR-negative tests has an implication on the severity of the above-mentioned psychiatric manifestations.
METHODS: Socio-demographic characteristics of 200 post-COVID-19 patients were collected, and also, the self-assessment anhedonia scale was used to evaluate the degree of anhedonia. Fatigue assessment scale used to investigate this domain. The study targeted to find a possible correlation between the period after recovery and the other variables including anhedonia and fatigue.
RESULTS: The study revealed high scores of different subtypes of self-assessment anhedonia scale (including total intensity, total frequency, and total changes scores) in the studied group, also high score of fatigue assessment scale in those patients. Positive statistically significant correlation between anhedonia and fatigue in post-COVID-19 group, also negative statistically significant correlation between duration after recovery and the other 2 variables(anhedonia and fatigue) in the examined patients.
CONCLUSION: Post-COVID-19 fatigue and anhedonia were prevalent and commonly reported in the post-COVID-19 period, also the duration after 2 consecutive negative PCR tests has an implication on the severity rating scale of both anhedonia and fatigue. These findings directed our attention to those reported manifestations which affected the socio-occupational functioning of the individuals during this whole world pandemic.
© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.

Entities:  

Keywords:  COVID-19; anhedonia; fatigue; pandemic; post-recovery

Mesh:

Year:  2020        PMID: 33332756      PMCID: PMC8182964          DOI: 10.1002/npr2.12154

Source DB:  PubMed          Journal:  Neuropsychopharmacol Rep        ISSN: 2574-173X


INTRODUCTION

Rothan and Byrareddy noted COVID‐19 is a viral infection caused by SARS‐CoV‐2 that principally affects the pulmonology system with primary manifestations like fever, cough, and shortness of breath. World Health Organization declared until the end of May 2020, there were over 5.5 million confirmed cases of people who have been infected with COVID‐19 worldwide and over 353 000 death cases. Xiang et al highlighted infection symptoms including fever, hypoxia and dry cough, shortness of breath, and adverse effects of treatment like corticosteroids induced insomnia might lead to anxiety worsening and mental distress . Rio and Malani highlighted that fatigue is commonly seen in COVID‐19 epidemic, and also, the patients still have high levels of fatigue and anhedonia after recovery from infection. Treadway and Zald defined anhedonia as persistently and severely decreased interest or pleasure in most daily activities. It is also known as a decrement of pleasurable activities, or a loss of interest to action in order to get pleasure. Brodaty et al found that anhedonia and fatigue can also occur in patients without psychiatric disorders like in systemic illnesses ,viral infections, or chronic fatigue syndrome. Similarly, apathy and anhedonia were recognized to occur not only in the context of clinical diagnoses but also, in milder forms, in the general population, particularly with aging. Brooks et al noted the effect of quarantine on cases of COVID‐19 infection leading to development of psychological and cognitive manifestations of post‐COVID‐19 depressive symptoms, stress, anxiety, chronic fatigue, and anhedonic state. Hives et al evidenced pro‐inflammatory components like cytokines such as interferon gamma, and interleukin 7, which supposed to compromise the neurological regulation of the “Glymphatic System” as observed in chronic fatigue syndrome. Perrin et al found that many cases of COVID‐19 developed a drastic post‐viral syndrome named “post‐COVID‐19 Syndrome”—a persistent condition of chronic fatigue, disturbed sleep/wake cycle, neuro‐cognitive implications, and progressive anhedonia.

METHODS

Settings

This study was conducted in Hayat National Hospital, Psychiatry Department, Riyadh, Kingdom of Saudi Arabia. The study was conducted from 10th of July to 28th of July 2020.

Study design

This current methodological design is a cross‐sectional observational study with a longitudinal component for evaluation of prevalence of anhedonia and fatigue in post‐COVID‐19 patients and the effect of duration after recovery from infection on the above‐mentioned domains.

Study population

A convenience sample of 200 patients of COVID‐19 after 2 consecutive negative PCR tests who attended for pulmonology clinic for follow‐up and psychiatric department for assessment.

Inclusion and exclusion criteria

All patients of both sexes, with age range from 18‐60 years, can read and write to complete the scales, 2 negative PCR tests for COVID‐19, those have major psychiatric disorders, other general medical conditions like chronic diseases that might be manifested by fatigue or under the effect of psychotropic medications were excluded from the study.

The self‐assessment anhedonia scale (SAAS)

This scale was developed by Olivares et al The scale included 27 items each to be replied on three independent semantic differential lines: 1. Intensity (a lot—not at all), 2. Frequency (always—never), and 3. Change (the same as before—less than before). Each line was 10 cm long and could be scored on a Likert‐type scale ranging from 0 to 10. The higher the score, the greater the anhedonia. To avoid halo effects, the second line polarities were reversed.

Fatigue assessment scale(FAS)

This scale was originated by Michielsen et al The FAS is a 10‐item scale evaluating symptoms of fatigue. Each item of the FAS is answered using a five‐point, Likert‐type scale ranging from 1 (“never”) to 5 (“always”). Items 4 and 10 are reverse‐scored. Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.

Ethical consideration

IRB approval was taken to conduct this study. Informed consent was obtained from all participants after full explanation of the aim of the study. Patients were confirmed about the confidentiality of their data collected and that they were able to withhold from the study at any time without giving reasons.

Statistical analysis

Data were analyzed using the Statistical Package of Social Science (SPSS) program for Windows (Standard version 24). The normality of data was first tested with one‐sample Kolmogorov‐Smirnov test. Qualitative data were described using number and percent. Continuous variables were presented as mean (SD) and two groups were compared by t test while ANOVA test was used to compare more than 2 group. The results were considered significant when (P ≤ .05). Pearson correlation was used to correlate continuous data.

RESULTS

Table 1 shows socio‐demographic data and clinical characteristics: The mean age of the participants was 36.58(SD ± 9.85) years. The sample composed of 114 male patients (57%) and 86 female patients (43%), 135(67.5%) were married while single were 65 (32.5%). 81 (40.5%) had an University degree those with secondary school were 79 (39.5%) and with intermediate school were 40 (20%), 103 (51.5%) of the sample were employed and 97 (48.5%) were unemployed. 126 (63%) were from urban areas. Smoker participants were 132 (66%).The mean duration after recovery from COVID‐19 was 11.83(SD ± 3.77).
TABLE 1

Socio‐demographic data among the studied group

Socio‐demographic dataThe studied group (n = 200)
Age/ years
Mean ± SD36.58 ± 9.85
≤30 y65 (32.5%)
30‐40 y61 (30.5%)
40‐50 y54 (27%)
≥ 50 y20 (10%)
Gender
Male114 (57%)
Female86 (43%)
Marital status
Married135 (67.5%)
Single65 (32.5%)
Education
Preparatory40 (20%)
Secondary79 (39.5%)
University81 (40.5%)
Occupation
Worker103 (51.5%)
Non worker97 (48.5%)
Residence
Urban126 (63%)
Rural74 (37%)
Smoking
Smokers132 (66%)
Non smokers68 (34%)
Mean duration after recovery from COVID‐19
Mean ± SD11.83 ± 3.77
Socio‐demographic data among the studied group Table 2 shows results distribution of self‐assessment anhedonia scale domains in which mean total intensity score was 224.02 (SD ± 20.72), mean total frequency score was 229.89 (SD ± 18.80), mean total change score was 234.87(SD ± 16.58), and mean total anhedonia score was 688.41(SD ± 52.98). Mean fatigue score was 40.81(SD ± 5.75).
TABLE 2

Distribution of self‐assessment anhedonia scale and fatigue assessment scale

The studied group (n = 200)
Mean total intensity score224.02 ± 20.72
Mean total frequency score229.89 ± 18.80
Mean total change score234.87 ± 16.58
Mean total anhedonia score688.41 ± 52.98
Mean Fatigue assessment scale score40.81 ± 5.75
Distribution of self‐assessment anhedonia scale and fatigue assessment scale Table 3 shows no statistically significant correlation between items of socio‐demographic data and mean total anhedonia score.
TABLE 3

Association between socio‐demographic data and total anhedonia score

Socio‐demographic dataTotalTotal ANHEDONIA scoreTest of significance P value
Age/years
<30 y65684.45 ± 51.31 F = 0.459.711
30‐40 y61686.44 ± 50.46
40‐50 y54695.41 ± 57.09
>50 y20688.45 ± 56.57
Gender
Male114692.17 ± 53.17 = 1.16.249
Female86683.43 ± 52.63
Marital status
Married135689.15 ± 55.67 = 0.284.777
Single65686.87 ± 47.29
Education
Primary40677.35 ± 51.88 F = 1.37.257
Secondary79694.30 ± 47.26
University81688.13 ± 58.29
Occupation
Worker103688.75 ± 51.43 = 0.094.925
Non worker97688.05 ± 54.85
Residence
Urban126689.52 ± 55.64 = 0.385.700
Rural74686.52 ± 48.42
Smoking
Smokers132687.15 ± 53.14 = 0.469.640
Non smokers68690.86 ± 52.98

F: ANOVA test, t: Student's t test.

Association between socio‐demographic data and total anhedonia score F: ANOVA test, t: Student's t test. Table 4 showed a statistically significant positive correlation between gender of the patient and fatigue assessment scale (t = 1.97, P value .05*).
TABLE 4

Association between socio‐demographic data and fatigue assessment scale

Socio‐demographic dataTotalFatigue assessment scaleTest of significance P value
Age/ years
<30 y6540.80 ± 5.39 F = 0.378.769
30‐40 y6140.39 ± 6.21
40‐50 y5441.46 ± 5.94
>50 y2040.35 ± 5.10
Gender
Male11441.50 ± 5.64 = 1.97.05*
Female8639.89 ± 5.81
Marital status
Married13541.18 ± 5.72 = 1.33.184
Single6540.03 ± 5.77
Education
Preparatory4039.52 ± 5.49 F = 1.29.276
Secondary7941.26 ± 5.45
University8141.00 ± 6.13
Occupation
Worker10341.24 ± 5.64 = 1.09.274
Non worker9740.35 ± 5.85
Residence
Urban12640.66 ± 5.91 = 0.484.629
Rural7441.07 ± 5.49
Smoking
Smokers13241.36 ± 5.56 = 1.91.058
Non smokers6839.73 ± 6.01

F: ANOVA test, t: Student.

Association between socio‐demographic data and fatigue assessment scale F: ANOVA test, t: Student. Table 5 revealed a statistically significant negative correlation between mean duration after recovery from COVID‐19 and different domains of self‐assessment anhedonia scale and fatigue assessment scale. Also, there was a statistically significant positive correlation between domains of self‐assessment anhedonia scale (SAAS) and fatigue assessment scale (FAS).
TABLE 5

Association between days after recovery from COVID‐19, fatigue assessment scale, and self‐assessment anhedonia scale

Days after recovery from COVID‐19Fatigue assessment scale
r P r P
Mean total intensity score−.760≤.001*.728≤.001*
Mean total frequency score−.631≤.001*.601≤.001*
Mean total change score−.559≤.001*.515≤.001*
Mean total anhedonia score−.711≤.001*.670≤.001*
Mean fatigue assessment scale score−.900≤.001*

The use of * means that this variable is statistically significant.

Association between days after recovery from COVID‐19, fatigue assessment scale, and self‐assessment anhedonia scale The use of * means that this variable is statistically significant. Figure 1 illustrated positive association between mean total anhedonia score and mean fatigue assessment scale which means both anhedonia and fatigue were commonly associated in the post‐COVID‐19 recovery period.
FIGURE 1

illustrated the association between mean fatigue score and mean anhedonia score [Colour figure can be viewed at wileyonlinelibrary.com]

illustrated the association between mean fatigue score and mean anhedonia score [Colour figure can be viewed at wileyonlinelibrary.com]

DISCUSSION

The aim of the study was to assess the prevalence of post‐COVID‐19 fatigue and anhedonia and the possible effect of duration of recover from the coronavirus pandemic to both anhedonia and fatigue, and to our knowledge, it is among the leading published research investigating the prevalence of fatigue and anhedonia in post‐COVID‐19 period. The current study found high score of fatigue in post‐COVID‐19 patients, this is in agreement with Huang, et al who noted that most patients in post‐COVID‐19 period developed muscle ache, arthralgia, weakness, fatigue, or myalgia. Also, this study concluded high scores of different domains of anhedonia which is unique and novel, this is in accordance with Préau et al study mentioned that anhedonia was very common in viral epidemic like HIV‐infected patients with highly active antiretroviral therapies. Also, this study was unique regarding evaluation not only the total anhedonia score but also: total intensity, total frequency, and total change scores which were not assessed by other studies during the period after recovery from COVID‐19. The current study evidenced positive correlation between fatigue and anhedonia in post‐COVID‐19 period, and this is in the same way of Zhang et al who said that 38% of people stopped going to workplace due to the pandemic in China,25% stopped working at all and experienced high levels of psychological distress, fatigue anxiety, post‐traumatic stress disorder, and anhedonia. Also, the study evaluated the onset of anhedonia and fatigue after 2 negative PCR tests of coronavirus leading to a finding of high scores of fatigue and anhedonia during the early days after recovery, this is in parallel with Goyal et al mentioned during the period next 2 weeks after cure from COVID‐19, patients gradually developed sad mood, anhedonia, lethargy, anorexia, insomnia, and easy fatiguability. In conclusion, post‐COVID‐19 fatigue and anhedonia were common after recovery from novel coronavirus infection that affecting the domains of life of the patients, also the duration after cure affected these 2 manifestations which evoked an important question: Are they a transient sequelae of infection or still persist even after recovery? , this needs more research.

Study limitations

The study needs more number of cases for more solid data, also the assessment was done once, and more frequent evaluation will be needed for further consolidated results.

CONFLICTS OF INTEREST

There are no conflicts of interest. AUTHORS CONTRIBUTIONS 1‐Samir El Sayed (corresponding author): interviewing the patients, data collection, and writing the manuscript. 2‐Doaa Shokry: statistical analysis, biostatics, and helping in data interpretation. 3‐Sarah Gomaa: collection of patients’ data and revision of manuscript.

INFORMED CONSENT

Informed consent was obtained from all participants after full explanation of the aim of the study.

APPROVAL OF THE RESEARCH PROTOCOL BY THE INSTITUTIONAL REVIEWER BOARD

IRB approval was taken to conduct this study.

REGISTRY AND REGISTRATION NO. OF THE STUDY/TRIAL

n/a.

ANIMAL STUDIES

n/a.
  14 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  COVID-19-New Insights on a Rapidly Changing Epidemic.

Authors:  Carlos Del Rio; Preeti N Malani
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

3.  Do people become more apathetic as they grow older? A longitudinal study in healthy individuals.

Authors:  Henry Brodaty; Annette Altendorf; Adrienne Withall; Perminder Sachdev
Journal:  Int Psychogeriatr       Date:  2009-12-15       Impact factor: 3.878

4.  [Anhedonia and depressive symptomatology among HIV-infected patients with highly active antiretroviral therapies (ANRS-EN12-VESPA)].

Authors:  M Préau; A Bonnet; A-D Bouhnik; L Fernandez; Y Obadia; B Spire
Journal:  Encephale       Date:  2007-10-24       Impact factor: 1.291

5.  Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period.

Authors:  Samir El Sayed; Doaa Shokry; Sarah Mohamed Gomaa
Journal:  Neuropsychopharmacol Rep       Date:  2020-12-17

6.  Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study.

Authors:  Lucy Hives; Alice Bradley; Jim Richards; Chris Sutton; James Selfe; Bhaskar Basu; Kerry Maguire; Gail Sumner; Tarek Gaber; Annice Mukherjee; Raymond N Perrin
Journal:  BMJ Open       Date:  2017-11-13       Impact factor: 2.692

7.  Into the looking glass: Post-viral syndrome post COVID-19.

Authors:  Ray Perrin; Lisa Riste; Mark Hann; Andreas Walther; Annice Mukherjee; Adrian Heald
Journal:  Med Hypotheses       Date:  2020-06-27       Impact factor: 1.538

Review 8.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.

Authors:  Hussin A Rothan; Siddappa N Byrareddy
Journal:  J Autoimmun       Date:  2020-02-26       Impact factor: 7.094

9.  Unprecedented disruption of lives and work: Health, distress and life satisfaction of working adults in China one month into the COVID-19 outbreak.

Authors:  Stephen X Zhang; Yifei Wang; Andreas Rauch; Feng Wei
Journal:  Psychiatry Res       Date:  2020-04-04       Impact factor: 3.222

10.  Fear of COVID 2019: First suicidal case in India !

Authors:  Kapil Goyal; Poonam Chauhan; Komal Chhikara; Parakriti Gupta; Mini P Singh
Journal:  Asian J Psychiatr       Date:  2020-02-27
View more
  16 in total

1.  Spotlight on non-motor symptoms and Covid-19.

Authors:  Silvia Rota; Iro Boura; Yi-Min Wan; Claudia Lazcano-Ocampo; Mayela Rodriguez-Violante; Angelo Antonini; Kallol Ray Chaudhuri
Journal:  Int Rev Neurobiol       Date:  2022-07-09       Impact factor: 4.280

2.  Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications.

Authors:  Loredana Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

3.  Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period.

Authors:  Samir El Sayed; Doaa Shokry; Sarah Mohamed Gomaa
Journal:  Neuropsychopharmacol Rep       Date:  2020-12-17

Review 4.  Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review.

Authors:  Ana Luiza Cabrera Martimbianco; Rafael Leite Pacheco; Ângela Maria Bagattini; Rachel Riera
Journal:  Int J Clin Pract       Date:  2021-06-02       Impact factor: 3.149

5.  Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients.

Authors:  Letizia Santinelli; Luca Laghi; Giuseppe Pietro Innocenti; Claudia Pinacchio; Paolo Vassalini; Luigi Celani; Alessandro Lazzaro; Cristian Borrazzo; Massimiliano Marazzato; Lorenzo Tarsitani; Alexia E Koukopoulos; Claudio M Mastroianni; Gabriella d'Ettorre; Giancarlo Ceccarelli
Journal:  Front Nutr       Date:  2022-01-12

Review 6.  SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.

Authors:  Evgenii Gusev; Alexey Sarapultsev; Liliya Solomatina; Valeriy Chereshnev
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

7.  Post-COVID-19 fatigue as a major health problem: a cross-sectional study from Missouri, USA.

Authors:  Sohaib Khatib; Taher Sabobeh; Adam Habib; Sangeeth John; Reynaldo Gomez; Satya Sivasankar; Amgad Masoud
Journal:  Ir J Med Sci       Date:  2022-04-18       Impact factor: 2.089

8.  Possible Mechanisms Underlying Neurological Post-COVID Symptoms and Neurofeedback as a Potential Therapy.

Authors:  Mária Orendáčová; Eugen Kvašňák
Journal:  Front Hum Neurosci       Date:  2022-03-31       Impact factor: 3.473

Review 9.  Psychological Symptoms in COVID-19 Patients: Insights into Pathophysiology and Risk Factors of Long COVID-19.

Authors:  Angel Yun-Kuan Thye; Jodi Woan-Fei Law; Loh Teng-Hern Tan; Priyia Pusparajah; Hooi-Leng Ser; Sivakumar Thurairajasingam; Vengadesh Letchumanan; Learn-Han Lee
Journal:  Biology (Basel)       Date:  2022-01-02

10.  Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19.

Authors:  Nancy Dreyer; Natalia Petruski-Ivleva; Lisa Albert; Damir Mohamed; Emma Brinkley; Matthew Reynolds; Stephen Toovey
Journal:  Int J Gen Med       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.